This list is an analysis based on recent market events. It's not an investment recommendation.
About
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Satsuma Pharmaceuticals stocks are traded under the ticker 1LV.STU.
Does Satsuma Pharmaceuticals pay dividends?▼
Yes, 1LV.STU dividends are paid quarterly. The last dividend per share was 0.14 . As of today, Dividend Yield (FWD)% is 0%.
How many employees does Satsuma Pharmaceuticals have?▼
As of November 3, 2026, the company has 25 employees.
In which sector is Satsuma Pharmaceuticals located?▼
Satsuma Pharmaceuticals operates in the Manufacturing sector.
When did Satsuma Pharmaceuticals complete a stock split?▼
Satsuma Pharmaceuticals has not had any recent stock splits.
Where is Satsuma Pharmaceuticals headquartered?▼
Satsuma Pharmaceuticals is headquartered in South San Francisco, United States.